Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Alumis Inc. Common StockNASDAQ: ALMS
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$1.14B, compared with -$698.19M a year earlier.
Context
- Retained earnings amounted to 202.8% of total assets at the end of Q2 FY2026, up 88.6 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -62.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (901.88M) USD
- Year-over-year change
- -36.9%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (901.88M) | -36.9% |
| FY2024 | 2024-12-31 | (658.55M) | -80.8% |
| FY2023 | 2023-12-31 | (364.32M) | -74.0% |
| FY2022 | 2022-12-31 | (209.33M) | — |
Retained Earnings vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -62.9% is the lowest of 9, against a peer median of -6.8%.
- Retained earnings amounts to 202.8% of total assets for ALMS, versus a peer median of 386.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | -$44.41M USD | +69.3% | — | 386.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | -€164.27M EUR | — | — | 99.2% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$354.07M USD | -32.6% | — | 334.2% |
| Mar 2026 | -€383.82M EUR | -12.7% | — | 784.3% | |
| Mar 2026 | -$468.15M USD | -22.1% | — | 468.7% | |
| Mar 2026 | -$487.41M USD | -5.9% | — | 733.1% | |
| Mar 2026 | -$825.44M USD | -3.4% | — | 250.4% | |
| Mar 2026 | -$987.61M USD | -7.6% | — | 497.0% | |
| Mar 2026 | -$1.01B USD | +26.4% | — | 201.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$1.14B USD | -62.9% | — | 202.8% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -6.8% | — | 386.4% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.